| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1092065347 |
| P356 | DOI | 10.1186/S12941-017-0239-4 |
| P932 | PMC publication ID | 5627446 |
| P698 | PubMed publication ID | 28974222 |
| P50 | author | Zhaogang Sun | Q79689415 |
| P2093 | author name string | Sha Liao | |
| Yuhui Xu | |||
| Jianan Wu | |||
| P2860 | cites work | Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis | Q21563671 |
| Organization of the mycobacterial cell wall: a nanoscale view | Q46878315 | ||
| Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases | Q47999151 | ||
| Study shows use of high doses of antibiotics to clear infections may have the potential to promote increased cross-resistance in clinics | Q87412493 | ||
| Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype | Q88102831 | ||
| Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? | Q95421909 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis patients. | Q50984506 | ||
| Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. | Q51168151 | ||
| Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. | Q51193311 | ||
| The impact of nutritional state on the duration of sputum positivity of Mycobacterium tuberculosis. | Q51295495 | ||
| Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations. | Q53659312 | ||
| A controlled comparison of cycloserine plus ethionamide with cycloserine plus thiacetazone in patients with active pulmonary tuberculosis despite prolonged previous chemotherapy. | Q54720290 | ||
| New insight into extremely drug-resistant tuberculosis: using atomic force microscopy | Q61708199 | ||
| N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans | Q67945332 | ||
| Two three-month treatment regimens for pulmonary tuberculosis | Q68278546 | ||
| [Minimum daily efficient dose of ethambutol: general review] | Q69692131 | ||
| Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome | Q70082718 | ||
| Phenytoin disposition in obesity. Determination of loading dose | Q70104016 | ||
| Enteropathy associated with the acquired immunodeficiency syndrome | Q70609075 | ||
| Ethambutol in the retreatment and primary treatment of tuberculosis: a four-year clinical investigation | Q70883211 | ||
| Comparative study of the treatment of pulmonary tuberculosis by a combination of rifampicin and isoniazid administered daily and twice weekly for a year | Q71794671 | ||
| Pharmacokinetic considerations in obesity | Q77752248 | ||
| Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease | Q81698631 | ||
| Tuberculosis pharmacotherapy: strategies to optimize patient care | Q83292700 | ||
| Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis | Q83998764 | ||
| Optimizing the dose of rifapentine to treat tuberculosis. It's elementary | Q86627011 | ||
| Extracellular DNA Required for Bacterial Biofilm Formation | Q22065541 | ||
| Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence | Q22122411 | ||
| Major facilitator superfamily | Q24548616 | ||
| Polyprenyl phosphate biosynthesis in Mycobacterium tuberculosis and Mycobacterium smegmatis | Q24548963 | ||
| Rising to the challenge: new therapies for tuberculosis | Q27011672 | ||
| In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis | Q28329600 | ||
| High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection | Q28343757 | ||
| Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis | Q28469011 | ||
| The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol | Q28487116 | ||
| Mycobacterium tuberculosis produces pili during human infection | Q28487408 | ||
| Whole-genome sequencing and social-network analysis of a tuberculosis outbreak | Q29614802 | ||
| Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q29616834 | ||
| The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance | Q30157518 | ||
| World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. | Q30377488 | ||
| Understanding pharmacokinetics to improve tuberculosis treatment outcome | Q30411703 | ||
| Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action | Q30419537 | ||
| Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA | Q30427912 | ||
| Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. | Q31080111 | ||
| Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study | Q31107101 | ||
| Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes | Q33521011 | ||
| Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. | Q33735589 | ||
| Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? | Q33770163 | ||
| The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. | Q33913686 | ||
| Effects of obesity on pharmacokinetics implications for drug therapy | Q34053786 | ||
| The drug/metabolite transporter superfamily | Q34082606 | ||
| Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. | Q34184543 | ||
| Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial | Q34458735 | ||
| Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients | Q34510679 | ||
| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis | Q34519945 | ||
| Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes | Q34561741 | ||
| An official ATS statement: hepatotoxicity of antituberculosis therapy | Q34571651 | ||
| Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects | Q34622156 | ||
| The methyl-branched fortifications of Mycobacterium tuberculosis | Q34657803 | ||
| Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. | Q34737913 | ||
| Toxic hepatitis with isoniazid and rifampin. A meta-analysis | Q34745978 | ||
| Multidrug efflux transporters in the MATE family. | Q34909208 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis | Q34967044 | ||
| Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection | Q35006626 | ||
| Genome-wide Mycobacterium tuberculosis variation (GMTV) database: a new tool for integrating sequence variations and epidemiology | Q35157690 | ||
| Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms | Q35159676 | ||
| Mycobacterium tuberculosis metabolism | Q35245286 | ||
| AIDS enteropathy | Q35462384 | ||
| Tuberculosis treatment and drug regimens | Q35663866 | ||
| The polyketide Pks1 contributes to biofilm formation in Mycobacterium tuberculosis | Q35688871 | ||
| Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. | Q35746184 | ||
| Mixed Infections and Rifampin Heteroresistance among Mycobacterium tuberculosis Clinical Isolates | Q35757559 | ||
| Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears | Q35912691 | ||
| Survival strategies of infectious biofilms | Q36003660 | ||
| Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis | Q36086373 | ||
| Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. | Q36094916 | ||
| The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance | Q36172383 | ||
| Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients | Q36368678 | ||
| Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy | Q36379388 | ||
| Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis | Q36461593 | ||
| Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis | Q36482760 | ||
| Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study | Q36512029 | ||
| Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms | Q36582845 | ||
| Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria | Q36931422 | ||
| Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana | Q37145913 | ||
| Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study | Q37388924 | ||
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial | Q37507802 | ||
| Evolution and transmission of drug-resistant tuberculosis in a Russian population | Q37611572 | ||
| Effect of obesity on the pharmacokinetics of drugs in humans | Q37672600 | ||
| Antibiotic resistance of bacterial biofilms | Q37690946 | ||
| The immune system vs. Pseudomonas aeruginosa biofilms | Q37767747 | ||
| Cerebrospinal fluid concentrations of antituberculosis agents in adults and children | Q37780003 | ||
| Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis | Q37783433 | ||
| Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review | Q37844702 | ||
| New treatment options for multidrug-resistant tuberculosis. | Q38024041 | ||
| Drug resistance to Mycobacterium tuberculosis: from the traditional Chinese view to modern systems biology | Q38179033 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis: an update | Q38213320 | ||
| Mycobacterium biofilms: factors involved in development, dispersal, and therapeutic strategies against biofilm-relevant pathogens | Q38235016 | ||
| The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets | Q38246564 | ||
| Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis | Q38763608 | ||
| Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. | Q38851434 | ||
| Evaluation of vitamin status in patients with pulmonary tuberculosis | Q39192363 | ||
| U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis | Q39668880 | ||
| Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted from the Mixed Infection and the Testing System | Q40727240 | ||
| A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis | Q41475312 | ||
| Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution | Q42054011 | ||
| Short intensified treatment in children with drug-susceptible tuberculous meningitis | Q42242579 | ||
| Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. | Q42456062 | ||
| Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis | Q42858670 | ||
| Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan. | Q43021101 | ||
| Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis | Q43203258 | ||
| Innovative strategies to overcome biofilm resistance. | Q43233956 | ||
| Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. | Q43266428 | ||
| Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis | Q43770234 | ||
| Ofloxacin population pharmacokinetics in patients with tuberculosis. | Q44030948 | ||
| High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? | Q44160147 | ||
| TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? | Q44377279 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis | Q46272585 | ||
| Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis | Q46448545 | ||
| Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis | Q46472374 | ||
| A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis | Q46784686 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | bacteria | Q10876 |
| tuberculosis | Q12204 | ||
| P304 | page(s) | 67 | |
| P577 | publication date | 2017-10-03 | |
| P1433 | published in | Annals of Clinical Microbiology and Antimicrobials | Q15765734 |
| P1476 | title | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes | |
| P478 | volume | 16 |
| Q64055255 | Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of |
| Q52629914 | Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. |
| Q92086058 | What will it take to eliminate drug-resistant tuberculosis? |
Search more.